PRELUDE THERAPEUTICS INC (PRLD)
US74065P1012 - Common Stock
PRELUDE THERAPEUTICS INC
NASDAQ:PRLD (9/18/2024, 8:23:20 PM)
Premarket: 2.5 +0.06 (+2.46%)2.44
-0.01 (-0.41%)
Company Profile
Prelude Therapeutics, Inc. is a clinical-stage oncology company, which engages in the development of novel precision cancer medicines. The company is headquartered in Wilmington, Delaware and currently employs 128 full-time employees. The company went IPO on 2020-09-25. The company has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789, PRT2527 and PRT3645. PRT3789 is a highly selective degrader of SMARCA2 protein, which along with SMARCA4, controls gene regulation through chromatin remodeling. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including those driven by MCL1, MYC and MYB. PRT3645 is a brain and tissue penetrant molecule that potently targets CDK4/6 with a biased selectivity for CDK4. PRT2527 is designed to be a potent and selective CDK9 inhibitor. Its MCL1 candidate, PRT1419, is designed to be a potent and selective inhibitor of the anti-apoptotic protein, MCL1.
Company Info
PRELUDE THERAPEUTICS INC
175 Innovation Boulevard
Wilmington DELAWARE 19803
P: 13024671280
CEO: Krishna Vaddi
Employees: 128
Website: https://preludetx.com/
PRLD News
6 days ago - ChartmillKeep an eye on the top gainers and losers in Friday's session, as they reflect the most notable price movements.Curious about what's happening in today's session? Check out the latest stock movements and price changes.
6 days ago - ChartmillTop movers in Friday's sessionCurious about what's happening in today's session? Check out the latest stock movements and price changes.
6 days ago - Prelude Therapeutics, IncorporatedPrelude Therapeutics’ SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial6 days ago - Prelude Therapeutics, IncorporatedPrelude Therapeutics’ SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial- Encouraging signs of anti-tumor activity including objective responses observed in patients with SMARCA4-mutated non-small cell lung cancer (NSCLC) and...
10 days ago - Prelude Therapeutics, IncorporatedPrelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 202410 days ago - Prelude Therapeutics, IncorporatedPrelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024PRT3789, a novel, highly-selective SMARCA2 degrader in patients with advanced solid tumors with a SMARCA4 mutation oral session presentation: September 13,...
PRLD Twits
Here you can normally see the latest stock twits on PRLD, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
